Anadrol and Ketoconazole Interaction: Monitor | Peptide Database

Stimulates thymocyte proliferation and enlarges thymic lobules. Activates T-helper cells and improves immune response. Restores chromatin structure and gene expression in aged lymphocytes. Long-term treatment increased mean lifespan 20-40% in rodent studies. Suppresses development of spontaneous and induced tumors. Promotes recovery in tissues exposed to radiation damage. Restores brush border membrane enzyme levels in aged animals. Enhances intestinal barrier function in aged rats.

Join others researching LGD-4033 — share findings, ask questions, and learn from real experiences LGD-4033 (Ligandrol) is a nonsteroidal investigational selective androgen receptor modulator (SARM) originally developed by Ligand Pharmaceuticals and later licensed to Viking Therapeutics (under the designation VK5211). It is one of the most widely studied SARMs in clinical trials, having completed Phase 1 safety studies in healthy volunteers and a Phase 2 trial evaluating its efficacy in patients recovering from hip fracture surgery. LGD-4033 was designed to provide anabolic benefits, specifically increased lean muscle mass and improved physical function, with reduced androgenic side effects compared to testosterone. In clinical studies, it demonstrated dose-dependent increases in lean body mass, leg press strength, and stair-climbing speed in hip fracture patients. LGD-4033 is broadly considered the most potent SARM for lean mass accrual, exceeding Ostarine (MK-2866) in anabolic potency at comparable doses. Despite promising clinical data, LGD-4033 is not approved by any regulatory agency for any medical indication. Its widespread use in performance enhancement contexts is based on a combination of clinical trial data, preclinical studies, and anecdotal reports. LGD-4033 binds to the androgen receptor with high affinity (Ki of approximately 1 nM), functioning as a potent and selective agonist in muscle and bone tissue. Like other SARMs, its tissue selectivity is mediated by differential cofactor recruitment: upon binding to the AR, LGD-4033 induces a receptor conformation that preferentially recruits coactivators expressed in skeletal muscle and bone, while showing minimal agonist activity in androgen-sensitive tissues such as the prostate and skin. In preclinical studies, LGD-4033 produced dose-dependent increases in muscle mass (levator ani weight) with significantly less stimulation of prostate weight compared to testosterone. At the molecular level, AR activation by LGD-4033 drives gene transcription pathways involved in protein synthesis, nitrogen retention, and myogenic differentiation in skeletal muscle. The compound also promotes osteoblast activity and bone mineral density through AR signaling in bone tissue. LGD-4033 does not undergo aromatization to estrogen and is not a substrate for 5-alpha reductase, so it does not produce estrogenic side effects (gynecomastia, water retention from estrogen) or DHT-mediated side effects (prostate enlargement, androgenic alopecia). However, as a potent exogenous AR agonist, LGD-4033 suppresses endogenous testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis in a dose-dependent manner. This suppression is generally considered more pronounced than that caused by Ostarine at equivalent effective doses, consistent with its greater AR binding affinity and anabolic potency.